Cannabis Agonist Reduces Non-Hodgkin Lymphoma Tumor Growth, Study
Says

June 26, 2008 - Stockholm, Sweden

Stockholm, Sweden: The administration of the cannabinoid agonist R(+)-
MA halts the spread and growth of cancerous tumors in animals with non-
Hodgkin lymphoma, according to preclinical data published in the
current issue of the International Journal of Cancer. Investigators at
the Karolinska Institute in Stockholm reported that mice treated with
R(+)-MA experienced a 40 percent reduction in tumor weight.

"The anti-proliferative and proapoptotic (stimulated cell death)
effects of cannabinoids make the endocannabinoid system a potential
new therapeutic target for individualized therapy in lymphomas,"
authors concluded.

Earlier this year, the journal Cancer Research reported that the
administration of cannabinoids halts the spread of a wide range of
cancers, including prostate cancer, breast cancer, lung cancer,
pancreatic cancer, and brain cancer.

NORML Deputy Director Paul Armentano has a review of pot's anti-cancer
properties online at the Huffington Post.

For more information, please contact Paul Armentano, NORML Deputy
Director. Full text of the study, "Expression of cannabinoid receptors
type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by
receptor activation," appears in the September issue of the
International Journal of Cancer.

   updated: Jun 26, 2008

© 2008 NORML • Read our Privacy Statement • Site by Communicopia.Net
and Red Aphid

NORML and the NORML Foundation: 1600 K Street NW, Suite 501,
Washington DC, 20006-2832
Tel: (202) 483-5500 • Fax: (202) 483-0057 • Email: norml@norml.org